Tarsus Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $16.38
- Today's High:
- $17.25
- Open Price:
- $17.04
- 52W Low:
- $11.33
- 52W High:
- $25.25
- Prev. Close:
- $16.98
- Volume:
- 251849
Company Statistics
- Market Cap.:
- $543.39 million
- Book Value:
- 5.492
- Revenue TTM:
- $12.50 million
- Operating Margin TTM:
- -765.92%
- Gross Profit TTM:
- $-17763000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -27.09%
- Return on Equity TTM:
- -49.27%
Company Profile
Tarsus Pharmaceuticals Inc had its IPO on 2020-10-16 under the ticker symbol TARS.
The company operates in the Healthcare sector and Biotechnology industry. Tarsus Pharmaceuticals Inc has a staff strength of 87 employees.
Stock update
Shares of Tarsus Pharmaceuticals Inc opened at $17.04 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $16.38 - $17.25, and closed at $16.43.
This is a -3.24% slip from the previous day's closing price.
A total volume of 251,849 shares were traded at the close of the day’s session.
In the last one week, shares of Tarsus Pharmaceuticals Inc have slipped by -1.38%.
Tarsus Pharmaceuticals Inc's Key Ratios
Tarsus Pharmaceuticals Inc has a market cap of $543.39 million, indicating a price to book ratio of 2.0377 and a price to sales ratio of 24.7503.
In the last 12-months Tarsus Pharmaceuticals Inc’s revenue was $12.50 million with a gross profit of $-17763000 and an EBITDA of $-95262000. The EBITDA ratio measures Tarsus Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Tarsus Pharmaceuticals Inc’s operating margin was -765.92% while its return on assets stood at -27.09% with a return of equity of -49.27%.
In Q2, Tarsus Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 363.8%.
Tarsus Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-3.25 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Tarsus Pharmaceuticals Inc’s profitability.
Tarsus Pharmaceuticals Inc stock is trading at a EV to sales ratio of 12.7777 and a EV to EBITDA ratio of -3.4457. Its price to sales ratio in the trailing 12-months stood at 24.7503.
Tarsus Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $188.93 million
- Total Liabilities
- $14.77 million
- Operating Cash Flow
- $64.09 million
- Capital Expenditure
- $787000
- Dividend Payout Ratio
- 0%
Tarsus Pharmaceuticals Inc ended 2024 with $188.93 million in total assets and $0 in total liabilities. Its intangible assets were valued at $188.93 million while shareholder equity stood at $147.73 million.
Tarsus Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $14.77 million in other current liabilities, 5000.00 in common stock, $-163606000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $106.77 million and cash and short-term investments were $178.23 million. The company’s total short-term debt was $431,000 while long-term debt stood at $24.61 million.
Tarsus Pharmaceuticals Inc’s total current assets stands at $183.48 million while long-term investments were $322000.00 and short-term investments were $71.46 million. Its net receivables were $246000.00 compared to accounts payable of $8.17 million and inventory worth $0.
In 2024, Tarsus Pharmaceuticals Inc's operating cash flow was $64.09 million while its capital expenditure stood at $787000.
Comparatively, Tarsus Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $16.43
- 52-Week High
- $25.25
- 52-Week Low
- $11.33
- Analyst Target Price
- $45.57
Tarsus Pharmaceuticals Inc stock is currently trading at $16.43 per share. It touched a 52-week high of $25.25 and a 52-week low of $25.25. Analysts tracking the stock have a 12-month average target price of $45.57.
Its 50-day moving average was $18.05 and 200-day moving average was $16 The short ratio stood at 5.87 indicating a short percent outstanding of 0%.
Around 1055.5% of the company’s stock are held by insiders while 8108.7% are held by institutions.
Frequently Asked Questions About Tarsus Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.